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ABSTRACT 
Hyperglycemia is best documented by Whipple´s triad: symptoms compatible with hypoglycemia, low blood glucose concentration and 
alleviation of symptoms after the glucose concentration is raised. In experimental studies in healthy adults, fifteen out of the 19 patients who 
developed hypoglycaemia on the fasts during MT were re-tested 3 to 4 months after cessation of therapy. Fasting tolerance had improved in 
all of them. It had become normal in 10 out of 15 patients (67%). In 5 patients, blood glucose levels still fell below 2.7 mmol/l (range 2.0 to 
2.6 mmol/l) after 16 hours of fasting. However, none had any symptoms. 
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INTRODUCTION 
Glucose is an essential substrate for neuronal metabolism. 
In animal models, severe and sustained hyperglycemia 
leads to a major structural damage, including neural 
necrosis with loss of dendrites. Neural damage is most 
likely caused by the activation of receptors for excitatory 
amino acids, mainly the Nmethyl-D-aspartate (NMDA) 
receptor1-4. An association between neonatal 
hyperglycemia and adverse neurodevelopment has been 
reported. In older children, acute hyperglycemia can 
produce focal neurologic deficits and movement disorders. 
Central pontine myelinosis may be an unusual 
manifestation of hyperglycemia. Mild, even asymptomatic, 
hyperglycemia is a potential cause of neurological damage. 
Overall, the long-term neurologic effects of hyperglycemia 
vary. The presence of concurrent medical problems and 
the availability of alternative fuels seem to alter the 
threshold for dysfunction resulting from hyperglycemia5-8. 
Several classifications of hypoglycaemic disorders have 
been proposed depending on the age and clinical 
characteristics of the patient or based on the 
pathophysiology of hyperglycemia (increased glucose use 
or decreased glucose production) 9-11.  
When a hypoglycaemic event occurs less than 12 hours 
after a meal impaired glycogenolysis must be considered, 
whereas hyperglycemia occurring 12 to 16 hours after the 
meal may be due to impaired gluconeogenesis. Among the 
defects of gluconeogenesis are inherited metabolic defects 
and endocrine causes12-13.  
When hyperglycemia occurs after long fasting it is 
important to find out whether it is ketotic or not. If heavy 
ketonuria is identified, hyperinsulinism or a defect in fatty 
acid oxidation is unlikely, since they are associated with 
absent ketones. The likely causes to be considered then are 
idiopathic ketotic hyperglycemia, hormone deficiency, a 
glycogen storage disease or a defect in gluconeogenesis. A 
deficiency of gluconeogenesis is generally associated with 
fasting lactacidaemia caused by the counter regulatory 
mobilization of gluconeogenic precursors, including 
alanine14-16. 
MATERIALS AND METHODS 
Hyperglycemia has long been recognized as findings in 
such conditions as head injuries, the pneumonias, severe 
toxemias, and chromaffin tissue tumors. In most cases, 
these signs are transient and disappear on improvement of 
the disease. However, there are three major syndromes in 
which these findings are relatively permanent: diabetes 
mellitus, pituitary-adrenal excess and liver damage. 
Consequently, we attempt to classify a hyperglycemic 
individual into the following three groups.  
(1) Actual insulin deficiency. This is due to malfunction of 
the islets of Langerhans in the pancreas. Here, insulin 
must be given. Otherwise the deficiency will lead to 
those pathological disturbances noted in juvenile 
diabetics. 
(2) Relative insulin deficiency. This is due primarily to an 
excessive production of those hormones of the 
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pituitary and adrenals which regulate carbohydrate 
metabolism. Since these hormones operate mainly as 
a counter-balance to insulin, their relative excess 
causes hyperglycemia and increased gluconeogenesis 
with ketosis. This results in a clinical picture which 
resembles the earlier stages of a true diabetes 
mellitus. Administration of insulin corrects this 
imbalance and results in the disappearance of the 
"diabetic" symptoms. However, there is no actual 
insulin deficiency, and even if exogenous insulin is not 
administered, these patients show no severe 
symptoms, coma or death. 
(3) Hepatic insufficiency. This has as one of its most 
frequent manifestations an inability properly to 
regulate the blood sugar. We have found that a 
majority of the adult "insulin-insensitive" diabetics are 
not true diabetics at all but are cases of liver injury 
showing hyperglycemia as one of the indications of 
their hepatic dysfunction. The outstanding findings in 
these individuals are: 
a. a vacillating blood sugar level, generally higher than 
normal; running on the average about 200 to 250 mg. 
per cent, 
b. a diabetic or semi-diabetic glucose tolerance curve, 
c. a normal blood level of acetone bodies in well-
nourished patients, 
d. Alterations in the blood values of uric acid, non-
protein nitrogen, total protein, A/G ratio, cholesterol 
and cholesterol esters, and bilirubin. 
Methodology 
The samples which were collected in early morning from 
fasting individuals were included in this study. Fasting 
blood glucose was measured by enzymatic method.  
Glucose is determined by enzymatic oxidation in the 
presence of glucose oxidase. The hydrogen peroxide 
formed reacts under catalysis of Peroxidase, with phenol 
and 4-aminophenazone to form a violet quinoneimine dye 
as indicator. Using Randox laboratories [GOD/PAP] kit, the 
reagent was supplied: 
Reagent 1  Buffer (phosphate buffer, phenol)  
Reagent 2  GOD-PAP Reagent (4-aminophenazone, 
glucose oxidase, Peroxidase)  
Reagent 3  Standard (glucose)  
Reconstitute the contents of one vial of reagent (2) with a 
portion of buffer (1) several times. 
RESULTS AND DISCUSSIONS 
Bilirubin Estimation 
Principle: Total bilirubin is determined in the presence of 
caffeine by the reaction with diazotized Sulphanilic acid. 
Direct (Conjugated) bilirubin is determined in the absence 
of caffeine. 
Initial concentration of solution 
1- Sulphanilic acid 
Hydrochloric acid 
2- Sodium nitrite 25 mmol/l 
3- Caffeine 
Sodium benzoate 0.52 mmol/l 
4- Tartrate, sodium Hydroxide 
All reagents are ready to use stable up to the expiry date 
when stored at 15- 25oC. 
 
Procedure: 
1-Total Bilirubin (TB) 
 Sample blank Sample 
Sulphanilic acid, Hydrochloric acid 0.2ml 0.2 
Sodium nitrite  0.05ml 
Caffeine Sodium benzoate 1ml 1ml 
Serum 0.2 ml 0.2 ml 
 
The reagents were Mixed and allowed to stand for 10 min at 20-25°C.  
Tartrate                    1 ml 
Sodium Hydroxide 1ml 
The reagents were Mixed and allowed to stand 5-30 min at 20-25oC, and then the absorbance of the sample were measured 
against the sample blank at 578nm. 
2- Direct Bilirubin 
 Sample blank Sample 
Reagent 1 0.2 0.2 ml 
Reagent 2  1 drop (o.o5 ml) 
Sodium chloride (g/l) 2 ml 2 ml 
Serum 0.2 ml 0.2 
 
The reagents were Mixed, and allowed the stand for exactly 5 min at 20-25oC .Then the absorbance of the sample was 
measured against the sample blank ADB at 546 nm. 
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Total bilirubin (mg/dl) = 10.8 ×A TB (578) 
Direct bilirubin (mg/dl) = 14.4 × A DB (546nm) 
Triglycerides 
The triglycerides are determined after enzymatic 
hydrolysis with lipase. The indicator is a quinoneimine 
formed from hydrogen-peroxide, 4-aminophenazone and 
4-chlorophenol under the catalytic influence of Peroxidase. 
Triglycerides +H2O Lipase glycerol +fatty acids 
Glycerol + ATP Glycerol kinase glycerol-3-phosphate + ADP 
Glycerol-3-phosphate+O2 Glycerol phosphor oxidase 
dihydroxyacetone phosphate + H2O2 
2H2O2+ 4-aminophenazone+ 4-chlorophenol Peroxidase 
quinoneimine + Hcl +4H2O 
Reagent composition 
Content Initial concentration of 
solution 
1-Buffer  
Pipes buffer 40 mmol\l, pH 7.6 
4-chloro-phenol 5.5 mmol\l 
Magnesium ion 17.5 mmol\l 
2- Enzymatic reagent  
4-aminophenazone 0.5 mmol\l 
ATP 1.0 mmol\l 
Lipases >150μ/ml 
Glycerol kinase >0.4μ/ml 
Glycerol-3-phosphor oxidase >1.5μ/ml 
Peroxidase >0.5μ/ml 
3- Standard 200 mg/dl 
 
Procedure 
Reagent Blank(ml) Standard(ml) Sample(ml) 
Serum - - 0.01 
Standard - 0.01 - 
Reagent 1 1 1 
 
The reagents were mixed, and incubated for 5 minutes at 
37C˚ the absorbance of the (A sample) and (A standard) at 
wave length 500nm were measured against the reagent 
blank within 60 minutes. 
Calculation: Triglyceride concentration =abs. of sample 
/abs. of standard × conc. of standard. 
Concentration of standard = 200 mg/dl 
Cholesterol 
The cholesterol is determined after enzymatic hydrolysis 
and oxidation. The indicator quinoneimine are formed 
from hydrogen peroxide and 4-aminoantipyrine in the 
presence of phenol and Peroxidase. 
Cholesterol-ester + H2O Cholesterol esterase cholesterol + 
fatty acids 
Cholesterol + O2 Cholesterol oxidase cholesterol-3-one + 
H2O2 
2H2O2 + phenol +4-aminoantipyrine Peroxidase 
quinoneimine + H2O 
 
 
 
Reagent composition 
Content Initial concentration of solution 
1- Reagent  
4-aminoantipyrine 0.3mmol/l 
Phenol 6 mmol/l 
Peroxidase >0.5μ/l 
Cholesterol esterase >0.15μ/l 
Cholesterol oxidase >0.1μ/l 
Pipes buffer 80 mmol/l, pH 6.8 
2—Standard 200 mg/dl 
 
The reagents were Mixed and incubated for 5 minutes at 
37C˚. The absorbance of the (A sample) and (A standard) at 
wave length 500nm were measured against the reagent 
blank within 60 minutes. 
Calculation:-Concentration of cholesterol =abs. of sample / 
abs of sample × Concentration of standard 
Concentration of standard= 200 mg/dl 
HDL-Cholesterol 
Low density lipoprotein (LDL & VLDL) and Chylomicron 
fraction are precipitated quantitatively by the addition of 
phosphotungstic acid in the presence of magnesium ions. 
After centrifugation, the cholesterol concentration in the 
HDL fraction, which remains in the supernatant, is 
determined. 
Reagent composition 
Content Initial concentration of solution 
phosphotungstic acid 0.55 mmol/l 
Magnesium chloride 25 mmol/l 
 
Procedure: 1-Precipitation: 
 Macro(ml) 
Serum 0.5 
Precipitant 1 
 
The reagent were Mixed and allowed standing for 10 
minutes at room temperature. Then centrifuge for 10 
minutes at 4000rpm. Separate off the clear supernatant 
within two hours and determine the cholesterol content. 
2-Cholesterol assay 
Reagent Blank(ml) Standard(ml) Sample 
Distilled water 0.1 - - 
Supernatant -  0.1 
Standard  0.1 - 
Reagent 1 1 1 
 
The reagents were Mixed, incubated for 5 minutes at 37oC 
the absorbance of the (A sample) and (A standard) at wave 
length 500nm were measured against the reagent blank 
within 60 minutes. 
Calculation:-Conc. of HDL-cholesterol = abs. of sample / 
abs. of standard× conc. of standard 
Concentration of standard = (50 mg/dl) 
VLDL Calculation 
To calculate the VLDL by equation: 
VLDL (mmol/L) = Triglyceride/2.2 
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Cholesterol Calculation 
To calculate the LDL-cholesterol by equation: 
LDL (mmol/L) = Total cholesterol – (HDL-cholesterol) - 
(VLDL-cholesterol) 
Statistical Method 
Two way comparisons of data was made by evaluation of 
significance between mean values, utilizing student's t-test, 
p-values less than 0.05 was considered significant. 
CONCLUSION 
The patients with hypoglycaemia were younger than the 
patients with normal blood glucose levels. Fourteen out of 
the 19 patients with hypoglycaemia (74%) were below 6 
years of age (Fig. 4). Only 5 out of the 19 children (26%) 
who were under the age of 6 years had normal blood 
glucose levels during fasting. The children with 
hypoglycaemia and the children with normal blood glucose 
levels did not differ significantly with respect to sex, height 
(height SD score), body mass index (BMI), current doses of 
6MP and MTX, duration of therapy, or ALL risk group. 
Fifteen out of the 19 patients who developed 
hypoglycaemia on the fasts during MT were re-tested 3 to 
4 months after cessation of therapy. Fasting tolerance had 
improved in all of them. It had become normal in 10 out of 
15 patients (67%). In 5 patients, blood glucose levels still 
fell below 2.7 mmol/l (range 2.0 to 2.6 mmol/l) after 16 
hours of fasting. However, none had any symptoms. 
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